{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:22:52Z","timestamp":1788906172540,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with type 2 diabetes mellitus (T2DM) undergoing percutaneous coronary intervention (PCI) are at high risk of adverse cardiovascular and renal outcomes. While both sodium\u2013glucose cotransporter-2 inhibitors (SGLT-2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i) are widely used in this population, direct evidence comparing their long-term efficacy and safety after PCI remains scarce. This meta-analysis aimed to compare cardiovascular and renal outcomes between SGLT-2i and DPP-4i in patients with T2DM post-PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Web of Science, Scopus, and Cochrane CENTRAL were searched through June 2025. Primary outcomes were all-cause mortality, worsening renal function, and heart failure. We included primary studies and assessed the quality of studies using Newcastle Ottawa Scale. RevMan software was used to calculate hazard ratios (HR) estimates and 95% confidence intervals (CI) using the random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We analyzed the outcomes between SGLT-2i (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097,025 patients) and DPP-4i (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097,459 patients). The mean age was 62.7 years, and 77.4% were males. SGLT-2i significantly reduced all-cause mortality (HR\u2009=\u20090.65; 95% CI: 0.54\u20130.79;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and the risk of worsening renal function (HR\u2009=\u20090.15; 95% CI: 0.09\u20130.26;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). They also demonstrated a significant reduction in heart failure events (HR\u2009=\u20090.59; 95% CI: 0.48\u20130.74;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). For myocardial infarction, a non-significant trend toward risk reduction with SGLT-2i was observed (HR\u2009=\u20090.85; 95% CI: 0.72\u20131.02;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.08). For cerebrovascular accidents and the need for repeat revascularization (PCI\/CABG), no significant difference was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT-2i demonstrates more clinical benefits, and current evidence supports its initiation over DPP-4i in T2DM patients after PCI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-02080-1","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T11:04:33Z","timestamp":1767956673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular and renal outcomes of sodium\u2013glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients"],"prefix":"10.1186","volume":"18","author":[{"given":"Ahmed Samy","family":"Badran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ibrahim","family":"Gbreel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-1703","authenticated-orcid":false,"given":"Mahmoud","family":"Balata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2080_CR1","doi-asserted-by":"crossref","unstructured":"Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract [Internet]. 2018;138:271\u201381. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822718302031","DOI":"10.1016\/j.diabres.2018.02.023"},{"key":"2080_CR2","doi-asserted-by":"crossref","unstructured":"Leon BM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes [Internet]. 2015;6:1246. Available from: http:\/\/www.wjgnet.com\/1948-9358\/full\/v6\/i13\/1246.htm","DOI":"10.4239\/wjd.v6.i13.1246"},{"key":"2080_CR3","doi-asserted-by":"publisher","unstructured":"Armstrong EJ, Rutledge JC, Rogers JH. Coronary Artery Revascularization in Patients With Diabetes Mellitus. Circulation [Internet]. 2013;128:1675\u201385. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002114","DOI":"10.1161\/CIRCULATIONAHA.113.002114"},{"key":"2080_CR4","doi-asserted-by":"crossref","unstructured":"Konigstein M, Ben-Yehuda O, Smits PC, Love MP, Banai S, Perlman GY et al. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents. JACC Cardiovasc Interv [Internet]. 2018;11:2467\u201376. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879818320235","DOI":"10.1016\/j.jcin.2018.09.033"},{"key":"2080_CR5","doi-asserted-by":"publisher","unstructured":"Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferovi\u0107 PM, Wanner C. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol [Internet]. 2022;21:144. Available from: https:\/\/cardiab.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12933-022-01575-9","DOI":"10.1186\/s12933-022-01575-9"},{"key":"2080_CR6","doi-asserted-by":"crossref","unstructured":"Lo CWH, Fei Y, Cheung BMY. Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. Card Fail Rev [Internet]. 2021;7. Available from: https:\/\/www.cfrjournal.com\/articleindex\/cfr.2020.19","DOI":"10.15420\/cfr.2020.19"},{"key":"2080_CR7","doi-asserted-by":"crossref","unstructured":"Nauck M. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther [Internet]. 2014;1335. Available from: http:\/\/www.dovepress.com\/update-on-developments-with-sglt2-inhibitors-in-the-management-of-type-peer-reviewed-article-DDDT","DOI":"10.2147\/DDDT.S50773"},{"key":"2080_CR8","doi-asserted-by":"publisher","unstructured":"White WB, Baker WL. Cardiovascular Effects of Incretin-Based Therapies. Annu Rev Med [Internet]. 2016;67:245\u201360. Available from: https:\/\/www.annualreviews.org\/doi\/https:\/\/doi.org\/10.1146\/annurev-med-050214-013431","DOI":"10.1146\/annurev-med-050214-013431"},{"key":"2080_CR9","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med [Internet]. 2015;373:2117\u201328. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26378978","DOI":"10.1056\/NEJMoa1504720"},{"key":"2080_CR10","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med [Internet]. 2017;377:644\u201357. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28605608","DOI":"10.1056\/NEJMoa1611925"},{"key":"2080_CR11","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med [Internet]. 2019;380:347\u201357. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30415602","DOI":"10.1056\/NEJMoa1812389"},{"key":"2080_CR12","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2018.02.907","author":"AY Kluger","year":"2018","unstructured":"Kluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, Rosol ZP, et al. Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review. Rev Cardiovasc Med. 2018. https:\/\/doi.org\/10.31083\/j.rcm.2018.02.907.","journal-title":"Rev Cardiovasc Med"},{"key":"2080_CR13","doi-asserted-by":"crossref","unstructured":"Verma S. Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits. Am J Cardiol [Internet]. 2019;124:S36\u201344. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919311786","DOI":"10.1016\/j.amjcard.2019.10.028"},{"key":"2080_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317. https:\/\/doi.org\/10.1056\/NEJMoa1307684.","journal-title":"N Engl J Med"},{"key":"2080_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327. https:\/\/doi.org\/10.1056\/NEJMoa1305889.","journal-title":"N Engl J Med"},{"key":"2080_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1592\/phco.30.5.463","volume":"30","author":"JJ Neumiller","year":"2010","unstructured":"Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2010;30:463. https:\/\/doi.org\/10.1592\/phco.30.5.463.","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"key":"2080_CR17","doi-asserted-by":"crossref","unstructured":"Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C-C, Tomaniak M et al. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis [Internet]. 2020;295:45\u201353. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020300174","DOI":"10.1016\/j.atherosclerosis.2020.01.002"},{"key":"2080_CR18","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.4244\/EIJ-D-20-01250","volume":"17","author":"I Johansson","year":"2021","unstructured":"Johansson I, Dicembrini I, Mannucci E, Cosentino F. Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention. 2021;17:e618. https:\/\/doi.org\/10.4244\/EIJ-D-20-01250.","journal-title":"EuroIntervention"},{"key":"2080_CR19","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Natsuaki M, Morimoto T, Shiomi H, Ozasa N, Sakamoto H et al. Effect of Polypharmacy on Long-Term Mortality After Percutaneous Coronary Intervention. Am J Cardiol [Internet]. 2021;159:19\u201329. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34497005","DOI":"10.1016\/j.amjcard.2021.08.013"},{"key":"2080_CR20","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Morimoto T, Natsuaki M, Shiomi H, Ozasa N, Sakamoto H et al. Polypharmacy and Bleeding Outcomes After Percutaneous Coronary Intervention. Circ J [Internet]. 2024;88:CJ-23-0558. Available from: https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/6\/88_CJ-23-0558\/_article","DOI":"10.1253\/circj.CJ-23-0558"},{"key":"2080_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01474-z","volume":"21","author":"D Giugliano","year":"2022","unstructured":"Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol. 2022;21:42. https:\/\/doi.org\/10.1186\/s12933-022-01474-z.","journal-title":"Cardiovasc Diabetol"},{"key":"2080_CR22","doi-asserted-by":"publisher","unstructured":"Min SH, Yoon J, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev [Internet]. 2017;33. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/dmrr.2818","DOI":"10.1002\/dmrr.2818"},{"key":"2080_CR23","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al. Cochrane handbook for systematic reviews of interventions. Cochrane Handb. Syst. Rev. Interv. John Wiley & Sons; 2019.","DOI":"10.1002\/9781119536604"},{"key":"2080_CR24","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"2080_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5195\/jmla.2017.111","volume":"105","author":"WM Bramer","year":"2017","unstructured":"Bramer WM, Milic J, Mast F. Reviewing retrieved references for inclusion in systematic reviews using EndNote. J Med Libr Assoc. 2017;105:84\u20137.","journal-title":"J Med Libr Assoc"},{"key":"2080_CR26","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ottawa Hosp Res Inst. 2000."},{"key":"2080_CR27","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ [Internet]. 2003;327:557\u201360. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12958120","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2080_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01914-4","volume":"22","author":"YS Lyu","year":"2023","unstructured":"Lyu YS, Oh S, Kim JH, Kim SY, Jeong MH. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus. Cardiovasc Diabetol. 2023;22:185. https:\/\/doi.org\/10.1186\/s12933-023-01914-4.","journal-title":"Cardiovasc Diabetol"},{"key":"2080_CR29","doi-asserted-by":"crossref","unstructured":"Lee H-F, Chan Y-H, Chuang C, Li P-R, Yeh Y-H, Hsiao F-C et al. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium\u2013glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. Eur Hear J - Cardiovasc Pharmacother [Internet]. 2023;9:301\u201310. Available from: https:\/\/academic.oup.com\/ehjcvp\/article\/9\/4\/301\/6987272","DOI":"10.1093\/ehjcvp\/pvad004"},{"key":"2080_CR30","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1111\/dom.15565","volume":"26","author":"JH Kim","year":"2024","unstructured":"Kim JH, Lyu YS, Kim B, Kim MK, Kim SY, Baek K, et al. Cardiorenal outcomes and mortality after sodium-glucose cotransporter\u20102 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history. Diabetes Obes Metab. 2024;26:2567\u201377. https:\/\/doi.org\/10.1111\/dom.15565.","journal-title":"Diabetes Obes Metab"},{"key":"2080_CR31","doi-asserted-by":"crossref","unstructured":"Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G et al. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol [Internet]. 2023;81:2377\u201387. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723055055","DOI":"10.1016\/j.jacc.2023.04.034"},{"key":"2080_CR32","doi-asserted-by":"publisher","unstructured":"Su S, Ji X, Li T, Teng Y, Wang B, Han X et al. The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy. Front Cardiovasc Med [Internet]. 2023;10. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fcvm.2023.1291450\/full","DOI":"10.3389\/fcvm.2023.1291450\/full"},{"key":"2080_CR33","doi-asserted-by":"crossref","unstructured":"Brata R, Pascalau AV, Fratila O, Paul I, Muresan MM, Camarasan A et al. Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus\u2014A Narrative Review. Healthcare [Internet]. 2024;12:2464. Available from: https:\/\/www.mdpi.com\/2227-9032\/12\/23\/2464","DOI":"10.3390\/healthcare12232464"},{"key":"2080_CR34","doi-asserted-by":"crossref","unstructured":"Bray JJH, Foster-Davies H, Stephens JW. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res Clin Pract [Internet]. 2020;168:108368. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720306215","DOI":"10.1016\/j.diabres.2020.108368"},{"key":"2080_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102272","volume":"66","author":"M Chiriac\u00f2","year":"2022","unstructured":"Chiriac\u00f2 M, Tric\u00f2 D, Solini A. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors. Curr Opin Pharmacol. 2022;66:102272.","journal-title":"Curr Opin Pharmacol"},{"key":"2080_CR36","doi-asserted-by":"publisher","unstructured":"Pahud de Mortanges A, Salvador D Jr., Laimer M, Muka T, Wilhelm M, Bano A. The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review. Front Pharmacol [Internet]. 2021;12. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fphar.2021.751214\/full","DOI":"10.3389\/fphar.2021.751214\/full"},{"key":"2080_CR37","doi-asserted-by":"crossref","unstructured":"Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract [Internet]. 2019;150:8\u201316. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822718319338","DOI":"10.1016\/j.diabres.2019.02.014"},{"key":"2080_CR38","doi-asserted-by":"crossref","unstructured":"Huang X-D, Jiang D-S, Feng X, Fang Z-M. The benefits of oral glucose-lowering agents: GLP-1 receptor agonists, DPP-4 and SGLT-2 inhibitors on myocardial ischaemia\/reperfusion injury. Eur J Pharmacol [Internet]. 2024;976:176698. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924003868","DOI":"10.1016\/j.ejphar.2024.176698"},{"key":"2080_CR39","doi-asserted-by":"crossref","unstructured":"Muscoli S, Barill\u00e0 F, Tajmir R, Meloni M, Della Morte D, Bellia A et al. The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics [Internet]. 2022;14:1730. Available from: https:\/\/www.mdpi.com\/1999-4923\/14\/8\/1730","DOI":"10.3390\/pharmaceutics14081730"},{"key":"2080_CR40","doi-asserted-by":"publisher","unstructured":"Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Front Pharmacol [Internet]. 2022;13. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fphar.2022.800490\/full","DOI":"10.3389\/fphar.2022.800490\/full"},{"key":"2080_CR41","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H\u2009+\u2009exchanger, lowering of cytosolic Na\u2009+\u2009and vasodilation. Diabetologia. 2018;61:722\u20136. https:\/\/doi.org\/10.1007\/s00125-017-4509-7.","journal-title":"Diabetologia"},{"key":"2080_CR42","doi-asserted-by":"crossref","unstructured":"Massalha S, Luria L, Kerner A, Roguin A, Abergel E, Hammerman H et al. Heart failure in patients with diabetes undergoing primary percutaneous coronary intervention. Eur Hear J Acute Cardiovasc Care [Internet]. 2016;5:455\u201362. Available from: https:\/\/academic.oup.com\/ehjacc\/article\/5\/6\/455-462\/5918495","DOI":"10.1177\/2048872615598632"},{"key":"2080_CR43","doi-asserted-by":"publisher","unstructured":"Fonseca-Correa JI, Correa-Rotter R, Sodium-Glucose. Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med [Internet]. 2021;8. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fmed.2021.777861\/full","DOI":"10.3389\/fmed.2021.777861\/full"},{"key":"2080_CR44","doi-asserted-by":"crossref","unstructured":"Nusca A, Di Bitonto MP, Span\u00f2 A, Bernardini F, Mangiacapra F, Ricottini E et al. Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention. Am J Cardiol [Internet]. 2025;240:50\u20136. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925000153","DOI":"10.1016\/j.amjcard.2025.01.007"},{"key":"2080_CR45","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med [Internet]. 2019;380:2295\u2013306. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30990260","DOI":"10.1056\/NEJMoa1811744"},{"key":"2080_CR46","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med [Internet]. 2020;383:1436\u201346. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32970396","DOI":"10.1056\/NEJMoa2024816"},{"key":"2080_CR47","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY, Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med [Internet]. 2023;388:117\u201327. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36331190","DOI":"10.1056\/NEJMoa2204233"},{"key":"2080_CR48","doi-asserted-by":"publisher","unstructured":"Ul H, Ansari H, Ammar M, Mahboob E, Zulfiqar E, Uddin S et al. American Journal of Preventive Cardiology Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis \u2606. Am J Prev Cardiol [Internet]. 2025;21:100927. Available from: https:\/\/doi.org\/10.1016\/j.ajpc.2024.100927","DOI":"10.1016\/j.ajpc.2024.100927"},{"key":"2080_CR49","doi-asserted-by":"crossref","unstructured":"Senior PA, Houlden RL, Kim J, Mackay D, Nagpal S, Rabi D et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update \u2013 The User\u2019s Guide. Can J Diabetes [Internet]. 2020;44:592\u20136. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S149926712030229X","DOI":"10.1016\/j.jcjd.2020.08.002"},{"key":"2080_CR50","doi-asserted-by":"crossref","unstructured":"Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ et al. 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. Diabetes Metab J [Internet]. 2023;47:575\u201394. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37793979","DOI":"10.4093\/dmj.2023.0282"},{"key":"2080_CR51","doi-asserted-by":"crossref","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care [Internet]. 2023;46:S140\u201357. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36507650","DOI":"10.2337\/dc23-S009"},{"key":"2080_CR52","doi-asserted-by":"publisher","unstructured":"Wang Y-F, Kong X-H, Tao H-M, Tao L. The impact of triglyceride-glucose index on the prognosis of post-PCI patients\u2013a meta-analysis. Front Cardiovasc Med [Internet]. 2024;11. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fcvm.2024.1396865\/full","DOI":"10.3389\/fcvm.2024.1396865\/full"},{"key":"2080_CR53","doi-asserted-by":"crossref","unstructured":"Chen W, Liu Y, Shi Y, Liu J. Prognostic Value of Estimated Glucose Disposal Rate and Systemic Immune-Inflammation Index in Non-Diabetic Patients Undergoing PCI for Chronic Total Occlusion. J Cardiovasc Dev Dis [Internet]. 2024;11:261. Available from: https:\/\/www.mdpi.com\/2308-3425\/11\/9\/261","DOI":"10.3390\/jcdd11090261"},{"key":"2080_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02690-5","volume":"30","author":"S Shojaei","year":"2025","unstructured":"Shojaei S, Mousavi A, Arzhangzadeh A, Salabat D, Pourfaraji SM, Shirmard FO, et al. Estimated glucose disposal rate and the risk of major adverse cardio-cerebrovascular outcomes and mortality in patients undergoing percutaneous coronary intervention: a retrospective cohort study. Eur J Med Res. 2025;30:442. https:\/\/doi.org\/10.1186\/s40001-025-02690-5.","journal-title":"Eur J Med Res"},{"key":"2080_CR55","doi-asserted-by":"crossref","unstructured":"Shojaei S, Mousavi A, Soleimani H, Takaloo F, Roudsari PP, Salabat D et al. Time Trends in Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention. JACC Adv [Internet]. 2025;4:101526. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X24008068","DOI":"10.1016\/j.jacadv.2024.101526"},{"key":"2080_CR56","doi-asserted-by":"crossref","unstructured":"Takeji Y, Morimoto T, Shiomi H, Kato ET, Imada K, Yoshikawa Y et al. Sex Differences in Clinical Outcomes After Percutaneous Coronary Intervention. Circ J [Internet]. 2023;87:CJ-22-0517. Available from: https:\/\/www.jstage.jst.go.jp\/article\/circj\/87\/2\/87_CJ-22-0517\/_article","DOI":"10.1253\/circj.CJ-22-0517"},{"key":"2080_CR57","doi-asserted-by":"crossref","unstructured":"Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, G\u0105secka A. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. J Cardiovasc Dev Dis [Internet]. 2023;10. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37623335","DOI":"10.3390\/jcdd10080322"},{"key":"2080_CR58","doi-asserted-by":"crossref","unstructured":"Mousavi A, Shojaei S, Soleimani H, Semirani-Nezhad D, Ebrahimi P, Zafari A et al. Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr [Internet]. 2025;17:68. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39994802","DOI":"10.1186\/s13098-025-01635-6"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-02080-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:56:43Z","timestamp":1770983803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-02080-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2080"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-02080-1","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This meta-analysis was registered on PROSPERO. Registration Number: CRD420251077885.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registry number"}}],"article-number":"63"}}